| Dr Stacey A Kopp, MD | |
|
591 W Hollis St, Nashua, NH 03062-1323 | |
| (603) 577-4400 | |
| Not Available |
| Full Name | Dr Stacey A Kopp |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 591 W Hollis St, Nashua, New Hampshire |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316936503 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 13629 (New Hampshire) | Primary |
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386697803 PECOS PAC ID: 4183537509 Enrollment ID: O20031111000313 |
News Archive
AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.
New research suggests that antibiotic treatment could be asymptomatically inducing the transmission of the healthcare-acquired infection, C. difficile, contributing to the outbreaks that have recently been widely reported in hospitals and other settings. A team of scientists have successfully mirrored the infection cycle of C. difficile by generating a 'mouse hospital' with conditions mimicking the human environment in which C. difficile is transmitted.
Scientists in Vienna have developed a new technique for producing vaccines for H1N1, 'swine flu', based on insect cells. The research, published today in the Biotechnology Journal, reveals how influenza vaccines can be produced faster than through the traditional method of egg-based production, revealing a new strategy for the fight against influenza pandemics.
In an expansion of its ongoing effort to promote the next generation of stem cell scientists, The New York Stem Cell Foundation (NYSCF) today named the first six NYSCF Investigators. Each of the NYSCF-Robertson and NYSCF-Helmsley Investigators will receive up to $1.5 million over the next five years to expand their own laboratories, train other scientists and foster innovative high-risk/high reward research to explore the therapeutic potential of stem cells derived from humans and model organisms.
› Verified 2 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.
New research suggests that antibiotic treatment could be asymptomatically inducing the transmission of the healthcare-acquired infection, C. difficile, contributing to the outbreaks that have recently been widely reported in hospitals and other settings. A team of scientists have successfully mirrored the infection cycle of C. difficile by generating a 'mouse hospital' with conditions mimicking the human environment in which C. difficile is transmitted.
Scientists in Vienna have developed a new technique for producing vaccines for H1N1, 'swine flu', based on insect cells. The research, published today in the Biotechnology Journal, reveals how influenza vaccines can be produced faster than through the traditional method of egg-based production, revealing a new strategy for the fight against influenza pandemics.
In an expansion of its ongoing effort to promote the next generation of stem cell scientists, The New York Stem Cell Foundation (NYSCF) today named the first six NYSCF Investigators. Each of the NYSCF-Robertson and NYSCF-Helmsley Investigators will receive up to $1.5 million over the next five years to expand their own laboratories, train other scientists and foster innovative high-risk/high reward research to explore the therapeutic potential of stem cells derived from humans and model organisms.
› Verified 2 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.
New research suggests that antibiotic treatment could be asymptomatically inducing the transmission of the healthcare-acquired infection, C. difficile, contributing to the outbreaks that have recently been widely reported in hospitals and other settings. A team of scientists have successfully mirrored the infection cycle of C. difficile by generating a 'mouse hospital' with conditions mimicking the human environment in which C. difficile is transmitted.
Scientists in Vienna have developed a new technique for producing vaccines for H1N1, 'swine flu', based on insect cells. The research, published today in the Biotechnology Journal, reveals how influenza vaccines can be produced faster than through the traditional method of egg-based production, revealing a new strategy for the fight against influenza pandemics.
In an expansion of its ongoing effort to promote the next generation of stem cell scientists, The New York Stem Cell Foundation (NYSCF) today named the first six NYSCF Investigators. Each of the NYSCF-Robertson and NYSCF-Helmsley Investigators will receive up to $1.5 million over the next five years to expand their own laboratories, train other scientists and foster innovative high-risk/high reward research to explore the therapeutic potential of stem cells derived from humans and model organisms.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stacey A Kopp, MD 591 W Hollis St, Nashua, NH 03062-1323 Ph: (603) 577-4400 | Dr Stacey A Kopp, MD 591 W Hollis St, Nashua, NH 03062-1323 Ph: (603) 577-4400 |
News Archive
AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.
New research suggests that antibiotic treatment could be asymptomatically inducing the transmission of the healthcare-acquired infection, C. difficile, contributing to the outbreaks that have recently been widely reported in hospitals and other settings. A team of scientists have successfully mirrored the infection cycle of C. difficile by generating a 'mouse hospital' with conditions mimicking the human environment in which C. difficile is transmitted.
Scientists in Vienna have developed a new technique for producing vaccines for H1N1, 'swine flu', based on insect cells. The research, published today in the Biotechnology Journal, reveals how influenza vaccines can be produced faster than through the traditional method of egg-based production, revealing a new strategy for the fight against influenza pandemics.
In an expansion of its ongoing effort to promote the next generation of stem cell scientists, The New York Stem Cell Foundation (NYSCF) today named the first six NYSCF Investigators. Each of the NYSCF-Robertson and NYSCF-Helmsley Investigators will receive up to $1.5 million over the next five years to expand their own laboratories, train other scientists and foster innovative high-risk/high reward research to explore the therapeutic potential of stem cells derived from humans and model organisms.
› Verified 2 days ago
Patricia Lee Sargent, DO Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 280 Main St, Suite 410, Nashua, NH 03060 Phone: 603-595-7388 Fax: 603-595-8624 | |
John Thompson, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2565 | |
Dr. Jennifer Page, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 155 Kinsley St, Nashua, NH 03060 Phone: 603-889-6671 | |
Dr. Ranjan N Dandekar, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 280 Main St Ste 410, Nashua, NH 03060 Phone: 603-595-7388 | |
Anjana Neupaney, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 22 Prospect St, Nashua, NH 03060 Phone: 603-883-1626 Fax: 603-881-9914 | |
Dr. Cara Douville Kaupp, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 383 E Dunstable Rd, Nashua, NH 03062 Phone: 603-891-0083 Fax: 603-891-0847 | |
Dr. Valerie Atkins, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2616 Fax: 603-577-2084 |